MedTrace Logo

GSK2239633 FTIH Study

NCT01371812 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-07-21

No results posted yet for this study

Summary

The purpose of this first time into human study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633 in healthy male subjects.

Conditions

Interventions

DRUG

GSK2239633

Drug will be orally administered at the doses and time points detailed in the 'arms' section.

DRUG

Placebo

Placebo will be orally administered to 4 subjects in each treatment period of each cohort.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-29
Primary Completion
2011-07-01
Completion
2011-07-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01371812 on ClinicalTrials.gov